
In today’s briefing:
- The Nikkei Semiconductor Index Rebalance, Kioxia, Nikkei Volatility Hedge
- Primer: Right On Co Ltd (7445 JP) – Nov 2025
- Mitsui Kinzoku: Q2 FY2025 Upgrade Resets Earnings Baseline; Engineered Materials Accelerate
- Primer: Cybozu Inc (4776 JP) – Nov 2025
- Kissei Pharmaceutical (4547 JP): Guidance Upward Revision a Positive; Beova & Tavneos Still Key
- LaKeel (4074 JP) – Guidance Unchanged, Visibility Needed
- (19 Nov 2025) Mamezo(202A JP) — Fisco Company Research
- (19 Nov 2025) Mamezo — Fisco Company Research
- (20 Nov 2025) Toyoko <341A> — Fisco Company Research
- (20 Nov 2025) Caster <9331> — Fisco Company Research

The Nikkei Semiconductor Index Rebalance, Kioxia, Nikkei Volatility Hedge
- Kioxia set for inclusion in the Nikkei Semiconductor Index next week, alongside JX Advanced Metals, less than one day’s average daily volume in passive inflow at the close.
- Kioxia’s Q2 2025 results show an accelerating QoQ recovery and solid Q3 2025 forecasts, driven by high demand from data center and smart device products, confirming effective business structure reform.
- Stock is fairly valued after 2025 rally, potential weaknesses being value metrics such as P/E alongside execution of margin and product pipeline targets.
Primer: Right On Co Ltd (7445 JP) – Nov 2025
- Right On Co. Ltd. is a jeans and casual wear retailer facing a prolonged period of declining revenues and significant financial losses, driven by intense competition and shifting consumer preferences in the Japanese apparel market.
- Despite a challenging top-line trend, the company has shown some recent, albeit inconsistent, improvement in net income, suggesting that cost control measures may be taking effect. However, operating and free cash flows remain deeply negative, raising concerns about long-term sustainability.
- The company’s strategy is centered on its core competency in denim, leveraging both national and private brands, and optimizing its nationwide network of stores, which are primarily located in shopping centers. A pivot towards enhancing e-commerce and adapting product assortments to local tastes is critical for a potential turnaround.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Mitsui Kinzoku: Q2 FY2025 Upgrade Resets Earnings Baseline; Engineered Materials Accelerate
- FY2025 operating profit sharply upgraded; earnings base rebased higher across FY2026–28.
- Engineered Materials accelerating with VSP™ and FaradFlex® capacity expansions; ~25–30% OP CAGR implied.
- Metals more resilient than expected; ¥50 bn buyback supports valuation despite recent re-rating.
Primer: Cybozu Inc (4776 JP) – Nov 2025
- Cybozu is a dominant player in the Japanese groupware market, capitalizing on the nationwide push for digital transformation (DX). Its flagship no-code/low-code platform, Kintone, is a key growth driver, empowering businesses to create custom applications and streamline workflows.
- The company exhibits a strong financial track record, characterized by consistent double-digit revenue growth and improving profitability. The shift to a cloud-first, SaaS-based model has resulted in high gross margins and recurring revenue streams.
- Strategic focus is on expanding Kintone’s adoption within large enterprises and accelerating international growth, particularly in Southeast Asia. Investments in a partner ecosystem and new technologies like generative AI are expected to support long-term expansion, though they may impact short-term margins.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Kissei Pharmaceutical (4547 JP): Guidance Upward Revision a Positive; Beova & Tavneos Still Key
- Kissei Pharmaceutical (4547 JP) reported 7.9% YoY jump in revenue during H1FY26 driven by Beova, Tavneos and IT services amidst price revision pressures and generic competition.
- Kissei beat their H1FY26 guidance numbers. This compelled the company to revise their FY26 guidance numbers upwards.
- An NDA application was submitted in Japan in February 2025 for Linzagolix. The next big trigger would be Linzagolix receiving the approval for treatment of uterine fibroids in Japan.
LaKeel (4074 JP) – Guidance Unchanged, Visibility Needed
- Following on from a strong set of earnings in the previous quarter and an upward revision to FY guidance, Q1-3 FY12/25 results were a negative surprise, with both sales and OP being flat to down YoY.
- Results were impacted by Licence opportunities not closing as planned, and Consulting and Professional Services experiencing slower activity levels.
- Atypical for the company, Q3 FY12/25 OPM was negative, partly due to one-time event costs.
(19 Nov 2025) Mamezo(202A JP) — Fisco Company Research
Key points (machine generated)
- FISCO Ltd. anticipates a positive outlook due to strategic investments in AI robotics, with limited tariff risk impact.
- The projected price-to-earnings ratio (PER) is between 30 to 60 times, indicating strong growth expectations.
- The company revised its dividend forecast to 30.00 yen interim and 31.00 yen full-year, with a target payout ratio of 50% to 70%.
This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.
(19 Nov 2025) Mamezo — Fisco Company Research
Key points (machine generated)
- FISCO Ltd.’s report indicates diminishing tariff risks and growth potential from AI robotics investments.
- The company has a price-earnings ratio forecast of 30 to 60 times and revised its interim dividend to 30.00 yen per share.
- Despite stock price increases, the dividend yield is approximately 2%, with a target payout ratio of 50% to 70%.
This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.
(20 Nov 2025) Toyoko <341A> — Fisco Company Research
Key points (machine generated)
- FISCO Ltd.’s report highlights Toyoko’s transition of the CoolLaser business from R&D to monetization, projecting over 50% CAGR with 120 units sold.
- The stock price has risen post-listing, indicating investor confidence in Toyoko’s profit growth and favorable PER evaluation similar to AI sectors.
- The report anticipates record profits for the fiscal year ending March 2026, driven by increasing demand from aging infrastructure globally.
This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.
(20 Nov 2025) Caster <9331> — Fisco Company Research
Key points (machine generated)
- Caster, listed on the Tokyo Stock Exchange Growth Market in October 2023, reported increased revenue but an operating loss for the fiscal year ending August 2025.
- The company focuses on alleviating labor shortages for SMEs by connecting them with remote workers, promoting remote work normalization.
- Caster has over 5,800 users, primarily from startups and SMEs, employs around 800 individuals, and operates entirely remotely.
This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.